Avalo Therapeutics, a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit.
Health Technology Insights: Lindus and Frieda Complete Menopause Treatment Trial
“Kevin joins Avalo at an exciting time, as we continue to advance AVTX-009 through the Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with topline data expected mid next year,” said Michael Heffernan, Chairman of the Board. “Kevin has an excellent track record of unlocking and delivering value to his shareholders through sound financial and corporate strategy and business development execution and I look forward to Avalo benefiting from his experience and leadership.”
Health Technology Insights: RazorMetrics Saves Texans $34 Million on Prescriptions in 2 years
“I have been fortunate to spend my career operating and building successful life science companies, always with the goal of translating strong science into meaningful outcomes for patients,” said Mr. Lind. “HS is rapidly emerging as one of the most exciting new therapeutic areas in inflammation and immunology, with tremendous opportunity to address the urgent needs of patients living with this devastating disease. Avalo’s approach with AVTX-009 has the potential to become a best in disease treatment, and I am eager to bring my experience to help advance Avalo’s mission of delivering transformative medicines to patients.”
Mr. Lind is a seasoned biotechnology executive with more than 20 years of leadership experience. He most recently served as President, Chief Executive Officer, and Board Member of Longboard Pharmaceuticals, where he led and transformed the Arena spinout into a leader in neurology and oversaw its $2.6 billion acquisition by H. Lundbeck A/S in 2024. Prior to his time at Longboard, Mr. Lind was Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals, where he played a central role in its turnaround, including lucrative business development partnerships and execution of its spinout of Longboard in 2020. Over the course of his career, Mr. Lind has raised more than a billion dollars in capital to support innovative biotech companies. He began his career in investment banking at Lehman Brothers before joining TPG, where he focused on healthcare investing. In addition to his role with Avalo, Mr. Lind currently serves as Chairman of the Board of Apnimed, Inc. He received a BS from Stanford University in Biological Sciences and an MBA from UCLA Anderson School of Management.
Health Technology Insights: Fitnescity Health launches CT Calcium Score test platform
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- GlobeNewswire
